SCREENING OF PCSK9 GENETIC VARIANTS IN FAMILIAL HYPERCHOLESTEROLEMIA (FH) PATIENTS IN A COHORT OF SRI LANKAN POPULATION

Hewa SP¹, Wetthasinghe KT², H.W. Dissanayake³

¹Department of Chemical Pathology, Colombo South Teaching Hospital, Kalubowila
²Human Genetic Unit, Faculty of Medicine, University of Colombo
³ Human Genetic Unit, Faculty of Medicine, University of Colombo

samanchempath@gmail.com
ABSTRACT

Background:
A hereditary predisposition for elevated serum levels of low-density lipoprotein cholesterol (LDL-C) leading to cardiovascular disease is a typical Familial hypercholesterolemia (FH) which affects approximately 1 in 250 individuals. In excess of thousand low-frequency variants in LDLR, APOB, and PCSK9 have been implicated in FH, but only few studies have been conducted at the population level. The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9), a secretory protein that posttranscriptionally regulates levels of low density lipoprotein receptor (LDLR) by inducing its degradation, has opened a new era of pharmacological modulation of cholesterol homeostasis. Nevertheless, certain mutations of the PCSK9 genes appear to hinder the expected results in certain patients. Thus, this study was aimed at designing of a novel PCR assay for the identification of PCSK9 genetic variants in a cohort of patients in Sri Lanka diagnosed with FH.

Method:
A comprehensive literature review was followed by designing of an allele specific PCR assay to genotype a total of 18 unrelated patients with a clinical diagnosis of familial hypercholesterolemia at the Human Genetics Unit, Faculty of Medicine, University of Colombo, Sri Lanka. The assay designed for the SNP rs11591147 G>T variant was validated using Sanger sequencing.
Results:

The expected band sizes at 428bp, 285bp and 188bp indicated the wild type allele, heterozygous allele and the homozygous allele for the pathogenic variant respectively. Out of the 18 patients tested, no heterozygotes or homozygotes the pathogenic variant was detected.

Conclusions:

This study is first of its kind to screen the PCSK9 genetic variants in FH patients in Sri Lanka. However, no pathogenic variations were identified which shows PCSK9 gene variants may be less significant in our population. Nevertheless, the designed assay will allow the application of precision medicine which will serve as paradigms for the prevention of premature atherosclerotic cardiovascular disease in all at-risk patients and families.

Key words

Familial Hypercholesterolemia, PCSK9, allele, genotype